

Role of Nano Technology in Developing Pharma Markets

Shiba Kalyan Giri*

PG Diploma in Management, ITM Business School, Warangal, Telangana, India

Review Article

Received: 27/09/2016

Accepted: 02/10/2016

Published: 09/10/2016

***For Correspondence**

Shiba Kalyan Giri, PG Diploma in Management, ITM Business School, Warangal, Telangana, India, Tel: 7873997451

Keywords: Marketing, Trends, E-marketing, Pharma, Nanotechnology

E-mail:

shibakalyan.giri6@gmail.com

ABSTRACT

The trends of marketing are changing day by day. Marketing started with the barter and now is in a finger tip of the people. It's not about how the companies are treating you but it also depends on the way you are updated to the current trends. The current trends of the market is addicted the customer in a way that only applications on the mobile phone and software's are playing a vital role in the day to day marketing activity of the consumer. In the busy schedule of life the companies are conserving the time by innovating the various app, home delivery, information sharing etc. The basic idea behind all those is only to save the time of the customer. This article we will discuss regarding the current trend of the Pharma Marketing to the market and society, necessary changes, delivered output.

INTRODUCTION

Nanotechnology in healthcare can be explained as the use of nanotechnology in healthcare. In reference to the human body, the role of nanotechnology in healthcare is to repair, construct, monitor and control the biological systems at molecular levels nanostructures and nano devices thereby diagnosing, preventing and treating the diseases. Nanotechnology finds its applications in major diseases like cancer, diabetes, musculoskeletal, cardiovascular, and infectious as well as neurodegenerative diseases. As the prevalence of these diseases is increasing worldwide nano technological products came into existence in market [1-3]. As discussed above, nanotechnology has role in diagnosis, prevention and treatment of diseases, there is an increased interest in research of in vitro diagnostics, biomaterials, and active implants. The main contribution is in the field of drug delivery especially in countries like Europe followed by US and Asia. Governments of those countries are also encouraging the research by providing funding. In aspect of commercialization, US stands about half of the world by marketing 40 to 50% of nanomedicine products.

Insights and gaining's from developing markets having prompted the rise of new plans of action, making a stage change in the working and business models of conventional markets. New markets in Africa and Asia have risen – Where once in the past just generics organizations played. Indonesia and Nigeria are driving the route in tending to the sheer size, land spread and characteristic difficulties of youthful populaces with elevated amounts of unmet need, pervasiveness of irresistible ailments and destitution. Management groups are assorted and routinely incorporate local people from developing markets. Pharmaceutical organizations have set up double brands, for certain developing markets, permitting all the more privately customized evaluating models, while counteracting parallel exchange [3-6]. Diabetes and particular tumours are currently the premier medicinal services issues in these rising economies, testing all partners to create arrangements [6-9]. Translational solution, including quality sequencing, has permitted developing markets to jump frog the West in a few components of examination. With Brazil and China the fundamental wellsprings of medication advancement, giving a noteworthy commitment to the answers for maturing and co-sullen populaces all around. IP assurance and administrative systems for working in BRICS and other developing markets have advanced and are presently caught on. Ability to oversee and run nearby organizations in differing societies and legitimate situations has enhanced and the quantity of associations has achieved a tipping point [10-15]. Emerging market governments perceive that inventive medications and worldwide pharmaceutical organizations have a part to play in their business sectors and have grown commonly advantageous connections. The exponential improvement of social insurance innovation has empowered rising nations to grow new more adaptable models of human services focussed on portable, high volume, minimal effort conveyance. In reaction pharmaceutical organizations have created customized systems that adjust to this more adaptable environment. Pharmaceutical organizations have put shrewdly in neighbourhood ability improvement activities which are paying profits [15-18].

By 2020 the present part of the pharmaceutical business' deals and showcasing workforce will be supplanted by another pattern as the business will be moved from an enormous mass-promoting to an objective business sector approach for expanding its income [19,20].

NANOTECHNOLOGY AND ITS FUTURE IN MARKETING

Nano products in medical field came into existence in market from a decade and some have their excellent role in therapeutics. The areas mainly focussed are cancer, CNS diseases, cardiovascular disease, and infection control. Out of these it has major contribution in cancer therapy. Other diseases including CNS disorders like Alzheimer's disease and stroke can also be treated by using nanotechnology providing for research in these areas. Nanotechnology has its application in autoimmune-related inflammatory disease by identifying successful products such as Remicade and Humira [21,22]. Enzon is among firms smartly following new development during this field, and new product ar expected to feature to the continued penetration of existing therapies, conducive to annual growth rates around V-J Day. In addition, technology

has contributed to a large kind of anti-infective product, from PEGylated interferons employed in infectious agent sickness to nanocrystalline silver used locally in wound infections. Biosanté and NanoBio are among firms actively concerned during this field. The United States of America market is far and away the biggest within the international nanomedicine market, and is about to still dominate the globe marketplace, however alternative national markets are expected to extend their shares over subsequent five years [23-25].

Here this article plots a conjunction of progression that leads to another showcasing and deals framework with a littler, more coordinated and more brilliant deals power. The Pharma business is never again being remunerated for incremental development, me-excessively items and offering the most pills [26-30]. Organizations should exhibit that their image increases the value of patients and they will bring to the table a bundle of items and wellbeing administrations that the business sector needs and needs as well as will pay a premium for. The paper highlights some exceptionally solid realities identified with the requirement for Pharma to change its advertising and deals capacities keeping in mind the end goal to maintain future development and execution [31-35].

This report highlights the central progression the business confronts that is reshaping the pharmaceutical commercial centre:

- ✓ Chronic illness is taking off
- ✓ Healthcare strategy producers and payers are progressively commanding what specialists can endorse
- ✓ Pay-for-execution is on the ascent
- ✓ The limits between various types of medicinal services are obscuring
- ✓ The markets of the creating scene, where interest for meds is liable to become most quickly throughout the following 13 years, are exceedingly differed
- ✓ Governments are starting to concentrate on anticipation as opposed to treatment
- ✓ Regulators are turning out to be more hazard opposed

With a specific end goal to be effective, organizations should stop the forceful promoting concentrating just on the result of the present model and:

- ✓ Recognise the reliance of the payer, supplier and pharmaceutical worth chains

- ✓ Invest in creating drugs the business sector needs to purchase
- ✓ Adopt a more adaptable way to deal with valuing
- ✓ Develop anticipates showcasing and offering pro treatments
- ✓ Manage multi-nation dispatches and live permitting
- ✓ Form a web of collusions to offer supporting administrations
- ✓ Create societies that are reasonable for promoting master medicinal services bundles
- ✓ Develop promoting and deals works that are fit for the future and a learning based business association

By 2020 the pharmaceutical business sector is expected to dramatically increase to US\$1.3 trillion, with the E7 nations – Brazil, China, India, Indonesia, Mexico, Russia and Turkey – bookkeeping around for one fifth of worldwide pharmaceutical deals. Further, frequency of constant conditions in the creating scene will progressively take after those of the created world [36-40].

PHARMA AND NANO TECHNOLOGY: THE VISION

Apart from targeted cancer therapy, engineering is being employed additional wide in making a replacement generation of drug delivery systems. A key think about its adoption is that nano scale particles have a bigger surface-to-volume quantitative relation than macro particles. Thus, a drug-bearing nanoparticle will unleash a drug additional quickly and additional extravagantly than larger particles. This is often useful once the drug poses issues with solubility and absorption, as is that the case with a substantial proportion of latest medication.

Already on the market within the U.S.A. square measure wound dressings that exploit the antimicrobial properties of nano crystalline silver. Ionic silver could be a powerful medicament, effective even against drawback organisms like MRSA, and engineering offers the simplest way to optimize its result once incorporated during a wound dressing.

While current medical nanotech applications target single nanoparticles and easy structures, future potentialities can involve comb such single components into structures which will perform additional advanced tasks than, as an example, emotional drug payloads. Thus, nanostructures could also be developed which will insert probes into electoral cells and inject DNA or macromolecule to correct genetic abnormalities.

Another risk is to style nanostructures which will foster and direct the regeneration of nerve cells;these would be employed in the treatment of stroke and trauma victims, and presumably for the restoration of

lost perform in Alzheimer's un wellness. However, a sober estimate of temporal arrangement would warn U.S.A. to not expect these developments to become reality till ten to twenty years from currently.

The nano medicine market is in early growth. Whereas nano-enhanced drug delivery product square measure already an ad reality, additional advanced nanotech-based medical devices square measure still in development, though some square measure at the clinical testing stage. Most of the cash being spent on the broader field of engineering R&D comes from government and established firms. Within the nano medicine field, pharmaceutical and specialist firms square measure at the forefront of analysis into the medical applications of engineering.

To date, drug delivery has been the most near-term chance for medical engineering. This market has Associate in Nursing calculable price of \$15.8 billion for 2014 and is forecast to grow to \$44.5 billion by 2019, to register a major CAGR of twenty third. The drug development class, the second fastest-growing chance, was projected at nearly \$12.6 billion for 2014 and is anticipated to extend to \$32.2 billion by a pair of019 at a twenty.7% CAGR. Demonstrates that the present pharmaceutical industry plan of action is both financially unsustainable and operationally unequipped for acting rapidly enough to create the sorts of inventive medications requested by worldwide markets. Keeping in mind the end goal to capitalize on these future development open doors, the industry should essentially change the way it works ^[41-45].

A portion of the real changes that we can forecast for the business are:

- a. Health consideration will move in centre from treatment to aversion.
- b. Pharmaceutical organizations will give complete human services bundles.
- c. The flow straight stage research and advancement procedure will offer approach to in-life testing and live authorizing, in a joint effort with controllers and human services suppliers.
- d. The conventional blockbuster deals model will vanish.
- e. The production network capacity will get to be income creating as it gets to be fundamental to the social insurance bundle and empowers access to new channels.
- f. More advanced direct-to-buyer dissemination channels will decrease the part of wholesalers.

Challenging Business Models

Most Big Pharma organizations have generally done everything from innovative work (R&D) through to commercialisation themselves. In any case, by 2020 this model will no more work for some associations. In the event that they are to flourish, they should enhance their R&D profitability, diminish their costs, tap

the capability of the rising economies and switch from offering drugs to overseeing results. These exercises few organizations, assuming any, can fulfil all alone [46-50].

This region clarifies how even the biggest pharmaceutical organizations will need to team up all the more intimately with players inside and outside the part to have the capacity to react to the requests from the distinctive partner groups. To do as such they will need to 'benefit together', by uniting with an extensive variety of associations, from scholastic foundations, doctor's facilities and innovation suppliers to organizations offering consistence programs, nutritious counsel, stress administration, physiotherapy, exercise offices and wellbeing screening [51-55].

The paper recommends that option plans of action with shifting degrees of joint effort will develop to give a premise to the business to work all the more adequately as times change. It additionally assesses the favourable circumstances and burdens of every option, their qualities and shortcomings and records some key inquiries to make the move to another business fruitful [56-60].

Taxing Times Ahead

It concentrates on the difficulties ahead additionally indicates how organizations can adjust their duty wanting to bolster the arrangement of results based social insurance and stay focused.

The report foresees that:

- A better approach for working together is inescapable, however new models will make charge arranging more mind boggling and increment the successful assessment rate for the business. Pharmaceutical organizations will shape more associations, cooperation and swing to M&A and also leaving on a system where they will give differing administrations past the customary item offering and to fill the item pipeline. This model could bring about the compelling duty rate to rise, make exchange valuing techniques more convoluted and conceivably result in a more prominent detach amongst income and expenses from an assessment perspective [61-65].
- An extended client base, made by more extensive access to medicinal services and developing populaces in developing markets will build gainfulness. Further, human services changes, innovation headways and other business sector powers are driving results centred social insurance conveyance. Pharmaceutical organizations should make more noteworthy esteem and show adequacy by moving from an absolutely item driven centre to a more extensive administration model, supplementing customary items with all-encompassing bundles of administrations to enhance understanding results. Expanded end-market administrations are saddled uniquely in contrast to items bringing about a movement in the taxation rate [66-70].

- There will be elevated rivalry amongst states and among developing business sector nations and those truly great to the business to pull in pharmaceutical and life sciences organizations through duty motivating forces. In that capacity, there will be a movement in benefit development toward the East and expanded outsourcing of assembling to developing markets ^[71-75].

- Long-term marketable strategies to develop, purchase, consolidation or offer will be the core, not the bit of hindsight, of duty methodology for pharmaceutical organizations. Later on, assessment technique will be considerably all the more firmly adjusted to business improvement system, and expense officials will involve an imperative seat at the table as Pharma organizations mull over plan of action changes ^[76-80].

Supplying the Future

Store network, the connection between the lab and the commercial centre, needs an intensive correction

Most Pharma have complex supply chains that are under-used, wasteful and not well outfitted to adapt to the kind of items descending the pipeline. This new report predicts that with a specific end goal to meet the requests of a quick advancing commercial centre and the movement from patient to result, the Pharma inventory network should experience a radical upgrade ^[81-83].

Various strengths are reshaping the earth in which the business works and directing the requirement for an alternate kind of store network

By 2020, the more various item sorts and treatments with shorter item lifecycles; new routes for evaluating, favoring and checking pharmaceuticals; expanding accentuation on results; new methods of conveying human services where the consideration is pushed into the group and where access to data on patients will get to be as imperative as the items themselves; the developing significance of developing markets; a more prominent open examination affecting the capacity to oversee danger and consistence; and, harder ecological controls and directions will oblige organizations to deliberately reassess their store network approach ^[84-87].

Convenient access to different developing innovations will expand the effectiveness of the assembling and circulation capacities

New advancements are rising to help Pharma organizations produce a more extensive and more mind boggling scope of meds, circulate them furthermore to speed the interface with the patient and getting nearer than at any other time ^[88-91].

Coordinated effort between the gatherings required in the human services arrangement will add to make the business more productive

The supply chains for outlining, producing and conveying pharmaceuticals and therapeutic gadgets in addition to those giving medicinal services administrations will incorporate with the goal that all accomplices can see the full picture and help them prepare all the more precisely and savvy ^[91-93].

What Course Ought to Organizations Take?

There are two choices for organizations concentrating on authority treatments and medications for vagrant illnesses and two choices for organizations concentrating on mass-market meds. Most organizations will can be categorized as one of those choices albeit substantial players may cover both closures of the range.

Virtual Research and Development

The pharmaceutical business is at a vital point in its advancement, especially in connection to innovative work. The patent on a hefty portion of the prescriptions dispatched in the 1990s will terminate throughout the following couple of years, leaving numerous organizations extremely uncovered; just four out of ten organizations have enough items in their pipelines to fill the approaching income crevice ^[94-96].

Pharma 2020: Virtual R&D - Which way will you take? Pharma 2020 arrangement, investigates how Pharma organizations could significantly enhance the R&D efficiency. It battles that by 2020 the R&D procedure might be abbreviated by 66%, achievement rates may significantly increment, and clinical trial expenses could be cut considerably. New PC based advances will make a more prominent comprehension of the science of infection and the development of "Virtual man"; to empower specialists to foresee the impacts of new medication hopefuls before they enter people. Alongside changes in progress in the administrative and socio-political environment, this will empower Pharma to defeat a standout amongst the most key issues it needs to determine throughout the following decade ^[97,98].

The second paper in the PwC Pharma 2020 arrangement, this report gives a visionary point of view on the change drivers that will affect innovative work efficiency and offer more noteworthy open doors for the improvement of all the more, really inventive items giving more noteworthy advantage to social insurance payers, suppliers and patients, and more prominent worth for the organizations included.

The report recommends new advancements and the advancement of a virtual R&D procedure will enhance our comprehension of the basic science of the human body and its illnesses, permitting specialists to better anticipate the impacts of new medication hopefuls before they enter people. It talks about the way that these progressions could empower the shortening of the R&D procedure by up to 66%, an emotional lessening in whittling down rates and a significant decrease in the expenses of clinical trials ^[99].

With a specific end goal to benefit from the open doors these progressions bear, the report investigates the suggestions for now's Pharma organization and the issues it must deliver on the off chance that it is to work most successfully in what will be a more associated and requesting world. These suggestions and the dangers and decisions included will shift crosswise over organizations. Run of the mill difficulties may incorporate;choosing which components of the advancement procedure to seek after and hold in-house versus getting to by means of new sorts of key association the operational changes expected to enhance velocity of reaction for the contrasting sorts of inventive medicines, the effect of moving from the current direct stage R&D process towards in-life testing and live permitting, ways to deal with teaming up all the more intimately with controllers and social insurance suppliers about estimating, showing adequacy, result advantage and esteem for cash, the future part of varying channels to showcase, the store network and the open doors this offers your association as a wellspring of income era, the suggestions for your plan of action and human capital issues ^[100].

CONCLUSION

The Pharmaceutical business' long fruitful technique of putting down huge wagers on a couple of particles, advancing them intensely and transforming them into blockbusters functioned admirably for a long time, yet its R&D profitability has now dove and the earth's evolving. In this article we finish up with the seven noteworthy patterns are reshaping the commercial centre:

- Instances of incessant sickness are expanding, putting considerably more prominent weight on effectively extended medicinal services spending plans
- Healthcare arrangement creators and payers are progressively commanding what specialists can recommend
- A developing number of social insurance payers are measuring the pharmaco economic execution of various drugs. A far reaching utilization of electronic restorative records will give them the information they have to demand results based estimating
- Boundaries between various types of human services are obscuring, as clinical advances render beforehand deadly ailments unending and the self-solution division extends
- Demand for pharmaceuticals is developing more quickly in the rising economies than the industrialized economies
- Governments are starting to concentrate on anticipation instead of treatment, despite the fact that they have not yet put particularly in pre-emptive measures; and
- Regulators are turning out to be more wary about affirming really inventive drugs.

These patterns will intensify the difficulties Pharma as of now faces, yet they'll likewise give some real open doors.

REFERENCES

1. Khan MA. Social Media's Influence on Hospitality & Tourism Management. J Bus Hotel Manage 2012;1:1.
2. McCool BN. The Need to be Prepared: Disaster Management in the Hospitality Industry. J Bus Hotel Manage 2012;1:2.
3. Weinstein RB. Servant Leadership: An Emerging Paradigm for Union-Management Relations. J Bus Hotel Manage 2012;1:1.
4. Adler H. Should We Really Care if Our Employees are Happy or Satisfied? J Bus Hotel Manage 2012;1:1.
5. Scharrer BL. Applying Theory of Planned Behaviour on Employees Intentions to Comply Code of Ethics: The Case of Comparison in between Germany/Austria and China. J Bus Hotel Manage 2016;3:1.
6. Akinci Z and Kasalak MA. Are Travel Agencies Ready for Accessible Tourism in Turkey? The Tendencies and Expectations of Travel Agencies as Supply Side of Accessible Tourism in Turkey. J Bus Hotel Manage 2016;3:1.
7. Nicely A. Networking Choices: How Hotel Managers can Boost their Learning from Networking. J Bus Hotel Manage 2016;2:1.
8. Mukherjee A and Sarma K. Assessment of Land Use Dynamics of Okhla Bird Sanctuary, Delhi Using Geospatial Technology. J Biodivers Manage Forestry 2016;5:1.
9. Potter C. Vegetation Cover Change in Glacier National Park Detected using 25 Years of Landsat Satellite Image Analysis. J Biodivers Manage Forestry 2016;5:1.
10. Bhat Mohd Skinder et al. Assessment of Floristic Diversity on the Bank of Nigeen Lake, Kashmir Valley. J Biodivers Manage Forestry 2016;5:1.
11. Silwal T et al. Injury Severity of Wildlife Attacks on Humans in the Vicinity of Chitwan National Park, Nepal. J Biodivers Manage Forestry 2016;5:1.
12. Mohammed AJ and Inoue M. Understanding REDD+ with Actor-Centered Power approach: A review . J Biodivers Manage Forestry 2016;5:1.
13. Lewis PA and Turcotte RM. Use of Chemical Protection and Host Tree Reduction to Control an Emerald Ash Borer Infestation in West Virginia. J Biodivers Manage Forestry 2015;4:1.
14. Aissaoui T. Novel Contribution to the Chemical Structure of Choline Chloride Based Deep Eutectic Solvents. Pharm Anal Acta. 2015;6:448.
15. Mworio JK, et al. Analgesic Potential of Acetone Leaf Extract of *Caesalpinia volkensii* harms in Mice. Pharm Anal Acta. 2015;6:450.

16. Kobayashi T and Tovar-Carrillo KL. Fibroblast Cell Cultivation on Wooden Pulp Cellulose Hydrogels for Cytocompatibility Scaffold Method. *Pharm Anal Acta*. 2015;6:423.
17. Bhusnure OG, et al. Drug Target Screening and its Validation by Zebrafish as a Novel Tool. *Pharm Anal Acta*. 2015;6:426.
18. Krithiga J and Briget MM. Synthesis of Agnps of Momordica charantia Leaf Extract, Characterization and Antimicrobial Activity. *Pharm Anal Acta*. 2015;6:427.
19. Gonzalez-Weller D, et al. Dietary Content and Evaluation of Metals in Four Types of Tea (White, Black, Red and Green) Consumed by the Population of the Canary Islands. *Pharm Anal Acta*. 2015;6:428.
20. Muriithi NJ, et al. Determination of Hematological Effects of Methanolic Leaf Extract of *S. incanum* in Normal Mice. *Pharm Anal Acta*. 2015;6:429.
21. Jana S, et al. Characterization of Physicochemical and Thermal Properties of Chitosan and Sodium Alginate after Biofield Treatment. *Pharm Anal Acta*. 2015;6:430.
22. Bhasin S and Patel R. Enhanced Oral Bioavailability of Alitretinoin by Lipid Drug Delivery System. *Pharm Anal Acta*. 2015;6:433.
23. Vadhana P, et al. Emergence of Herbal Antimicrobial Drug Resistance in Clinical Bacterial Isolates. *Pharm Anal Acta*. 2015;6:434.
24. Pawar HA and Yadav A. Development and Application of Rp-Hplc Method for Dissolution Study of Oral Formulations Containing Amlodipine Besylate. *Pharm Anal Acta*. 2015;6:437.
25. Kojima S, et al. Broadband Terahertz Time-Domain and Low-Frequency Raman Spectroscopy of Crystalline and Glassy Pharmaceuticals. *Pharm Anal Acta*. 2015;6:401.
26. Lin SY, et al. Effect of Povacoat or Soluplus on Solid-State Characterization of Indomethacin-Nicotinamide Co-Crystal Formation. *Pharm Anal Acta*. 2015;6:402.
27. Kino K, et al. Commentary on the Phototoxicity and Absorption of Vitamin B2 and Its Degradation Product, Lumichrome. *Pharm Anal Acta*. 2015;6:403.
28. Romkens TEH, et al. Urinary Excretion Levels of MMX-Mesalazine as a Tool to Assess Non-Adherence. *Pharm Anal Acta*. 2015;6:443.
29. Rashid MA, et al. Fluorescence Spectroscopic Study of Interaction between Olanzapine and Bovine Serum Albumin. *Pharm Anal Acta*. 2015;6:408.
30. Kumar R. An Analysis of Indian Pharma Trade and Future Challenges. *Pharm Anal Acta*. 2015;6:409.
31. Kumar S, et al. An Improved and Sensitive Method for Vitamin D3 Estimation by RP-HPLC. *Pharm Anal Acta*. 2015;6:410.
32. Lokesh BVS and Kumar PV. Enhanced Cytotoxic Effect of Chemically Conjugated Polymeric Sirolimus against HT-29 Colon Cancer and A-549 Lung Cancer Cell Lines. *J Pharm Drug Deliv Res*. 2015;4:2.
33. Scott D and Bae Y. Block Copolymer Crosslinked Nanoassemblies Co-entrapping Hydrophobic Drugs and Lipophilic Polymer Additives. *J Pharm Drug Deliv Res*. 2013;2:2.

34. Musirike MR, et al. Development and Validation of Reverse Phase-Ultra Performance Liquid Chromatographic Method for Estimation of Related Substances in Febuxostat Drug Substance. *Pharm Anal Acta*. 2015;6:431.
35. Andreotti R, et al. Diflubenzuron Effectiveness in Cattle Tick (*Rhipicephalus Boophilus microplus*) Control in Field Conditions. *Pharm Anal Acta*. 2015;6:373.
36. Radu CD, Parteni O, Popa M, Muresan IE, Ochiuz L, et al. Comparative Study of a Drug Release from a Textile to Skin. *J Pharm Drug Deliv Res*. 2015;4:2.
37. Pardhi D, et al. Evaluation of the Potential of Natural Biodegradable Polymers (Echinocloa Colonom Starch) and its Derivatives in Aqueous Coating of Hydrophilic Drugs. *J Pharm Sci Emerg Drugs*. 2016;4:1.
38. Kipping T and Rein H. Development of Extruded Starch Based Formulations Aimed for Local Drug Delivery to Oral Cavity. *J Pharm Drug Deliv Res*. 2012;1:1.
39. Gunjan J and Swarnlata S. Topical Delivery of Curcuma Longa Extract Loaded Nanosized Ethosomes to Combat Facial Wrinkles. *J Pharm Drug Deliv Res*. 2014;3:1.
40. Meier-Davis SR, et al. Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N,N-Dimethylaminopropionate (DDAIP). *J Pharm Drug Deliv Res*. 2012;1:1.
41. Vijayarajkumar P et al. Efavirenz Loaded Novel Citric Acid Dendritic Architecture for Increased Solubility and Sustained Delivery. *J Pharm Drug Deliv Res*. 2012;1:1.
42. Saxena Brij B, et al. Development of a Nanoporous Elastomere Intra-Vaginal Ring (IVR) for the Sustained Release of Non-Hormonal Contraceptives. *J Pharm Drug Deliv Res*. 2012;1:1.
43. Akintunde JK, et al. Sub-Chronic Treatment of Sildenafil Citrate (Viagra) on some Enzymatic and Non-enzymatic Antioxidants in Testes and Brain of Male Rats. *J Pharm Drug Deliv Res*. 2012;1:2.
44. Al-Malah KI. Prediction of Aqueous Solubility of Organic Solvents as a Function of Selected Molecular Properties. *J Pharm Drug Deliv Res*. 2012;1:2.
45. D'Cruz OJ, Uckun FM Targeting Spleen Tyrosine Kinase (SYK) for Treatment of Human Disease. *J Pharm Drug Deliv Res*. 2012;1:2.
46. Tarro G. Anti-Rhinovirus Activity of Ethyl 4-(3-(2-(3-Methylisoxazol-5-Yl) Ethoxy) Propoxy) Benzoate (EMEB). *Pharm Anal Acta*. 2016;7:469.
47. Sharma B et al. Formulation, Optimization and Evaluation of Atorvastatin Calcium Loaded Microemulsion. *J Pharm Drug Deliv Res*. 2012;1:3.
48. Zhou Y, et al. Therapeutic Effects of Sinomenine Microemulsion-Based Hydrogel on Adjuvant-Induced Arthritis in Rats. *J Pharm Drug Deliv Res*. 2012;1:3.
49. ElShaer, et al. Preparation and Evaluation of Amino Acid Based Salt Forms of Model Zwitterionic Drug Ciprofloxacin. *J Pharm Drug Deliv Res*. 2013;2:1.
50. Frank T. Population Pharmacokinetics of Lixisenatide, a Once-Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes. *J Pharm Drug Deliv Res*. 2013;2:1.
51. Akash MSH et al. Characterization of Ethylcellulose and Hydroxypropyl Methylcellulose Microspheres for Controlled Release of Flurbiprofen. *J Pharm Drug Deliv Res*. 2013;2:1.

52. Isabel S. Encapsulation of Fluoroquinolones in 1-Palmitoyl-2-Myristoyl-Phosphatidylcholine: Cholesterol Liposomes. *J Pharm Drug Deliv Res.* 2013;2:1.
53. Satya Krishna HP, et al. Solubility and Dissolution Enhancement of Candesartan Cilexetil by Liquid Compacts. *J Pharm Drug Deliv Res.* 2013;2:2.
54. Mohamed Idrees RY and Khalid A. Comparative Modeling of Serotonin Receptors 5ht2a and 5ht2c and In-silico Investigation of their Potential as Off-Target to Ethinylestradiol. *J Pharm Drug Deliv Res.* 2013;2:2.
55. Chopra AK, et al. Box-Behnken Designed Fluconazole Loaded Chitosan Nanoparticles for Ocular Delivery. *J Pharm Drug Deliv Res.* 2014;3:1.
56. Dey B, et al. Comparative Evaluation of Hypoglycemic Potentials of Eucalyptus Spp. Leaf Extracts and their Encapsulations for Controlled Delivery. *J Pharm Drug Deliv Res.* 2014;3:2.
57. Eftakis M and Siamidi A Design and Evaluation of a Multi-Layer Tablet System Based on Dextran. *J Pharm Drug Deliv Res.* 2014;3:2.
58. Humayoon R, et al. Quality Control Testing and Equivalence of Doxycycline Hyclate (100 mg) Capsule Brands under Biowaiver Conditions. *J Pharm Drug Deliv Res.* 2014;3:2.
59. Shin DG, et al. A Methylation Profile of Circulating Cell Free DNA for the Early Detection of Gastric Cancer and the Effects after Surgical Resection. *J Clin Exp Oncol.* 2016;5:1.
60. Brijesh KV, et al. Physicochemical Characterization and In-Vitro Dissolution Enhancement of Bicalutamide-Hp-B-Cd Complex. *J Pharm Drug Deliv Res.* 2015;3:2.
61. Panchangam RBS, et al. Engineered Nanoparticles for the Delivery of Anticancer Therapeutics. *J Pharm Drug Deliv Res.* 2015;4:1.
62. Olaso I, et al. A Comparative Study of the Treatment of Giardiasis with Commercially Marketed Medicine, Metronidazol with Compounding Medicine at a Rural Hospital in Ethiopia. *J Pharm Drug Deliv Res.* 2016;5:2.
63. Hasegawa H, et al. Sitagliptin Inhibits the Lipopolysaccharide-Induced Inflammation. *J Pharm Drug Deliv Res.* 2016;5:2.
64. Král V, et al. Multifunctional Bile Acid Derivatives as Efficient RNA Transporters (Carriers). *J Pharm Drug Deliv Res.* 2016;5:2.
65. Parvathi MVS, et al. Micro RNA-142-5p Profile as a Predictor of Tumor Markers Regulation in Different Histological Grades of Human Breast Carcinoma. *J Clin Exp Oncol.* 2016;5:2.
66. Kaliappan I, Structural Elucidation of Possible Metabolic Profile of Mangiferin by Oral and Intraperitoneal Administration. *J Pharm Drug Deliv Res.* 2015;4:1.
67. Coyne CP, Narayanan L Fludarabine-(C2-methylhydroxyphosphoramidate)-[anti-IGF-1R]: Synthesis and Selectively "Targeted" Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549). *J Pharm Drug Deliv Res.* 2015;4:1.
68. Koteswari P, et al. Fabrication of a Novel Device Containing Famotidine for Gastro Retentive Delivery Using Carbohydrate Polymers. *J Pharm Drug Deliv Res.* 2015;4:1.

69. Bassani AS, et al. In Vitro Characterization of the Percutaneous Absorption of Lorazepam into Human Cadaver Torso Skin, Using the Franz Skin Finite Dose Model. *J Pharm Drug Deliv Res.* 2015;4:2.
70. Satyavathi K, et al. Formulation and In-Vitro Evaluation of Liposomal Drug Delivery System of Cabazitaxel. *J Pharm Drug Deliv Res.* 2015;4:2.
71. Mahipalreddy D, et al. Preparation and Evaluation of Ketoprofen Enteric Coated Mini Tablets for Prevention of Chronic Inflammatory Disease. *J Pharm Drug Deliv Res.* 2015;4:2.
72. Ogaji IJ, OkaforIS, Hoag SW Some Characteristics of Theophylline Tablets Coated with Samples of Grewia Gum obtained from a Novel Extraction. *J Pharm Drug Deliv Res.* 2014;3:1.
73. Wiley TS, et al. H1R Antagonists for Brain Inflammation and Anxiety: Targeted Treatment for Autism Spectrum Disorders. *J Pharm Drug Deliv Res.* 2015;4:3.
74. Tsompos C, et al. The Effect of the Antioxidant Drug “U-74389G” on Uterus Inflammation during Ischemia Reperfusion Injury in Rats. *J Pharm Sci Emerg Drugs.* 2015;3:1.
75. Nair AK, et al. Development and Comparative Assessment of Hydrocolloid Based Against Wax Based Gastro Retentive Bilayered Floating Tablet Designs of Atorvastatin Calcium Using Qbd Approach. *J Pharm Drug Deliv Res.* 2015;4:3.
76. Ibtehal S, et al. Preparation of Zaleplon Microparticles Using Emulsion Solvent Diffusion Technique. *J Pharm Drug Deliv Res.* 2012;1:3.
77. Solomon AO, et al. Making Drugs Safer: Improving Drug Delivery and Reducing Side-Effect of Drugs on the Human Biochemical System. *J Pharm Drug Deliv Res.* 2015;4:4.
78. Orji JI, et al. Physicochemical Properties of Co-Precipitate of Plantain Peel Cellulose and Gelatin. *J Pharm Drug Deliv Res.* 2015;4:4.
79. Parteni O, et al. The Release of Tacrolimus from a Cotton Biomaterial to Dermis. *J Pharm Drug Deliv Res.* 2016;5:1.
80. Trivedi MK, et al. Characterization of Physical, Thermal and Spectral Properties of Biofield Treated O-Aminophenol. *Pharm Anal Acta.* 2015;6:425.
81. Strehlow B, Bakowsky U, Pinnapireddy SR, Kusterer J, Mielke G, et al. A Novel Microparticulate Formulation with Allicin In Situ Synthesis. *J Pharm Drug Deliv Res.* 2016;5:1.
82. Lee S, et al. Lifetime Assessment of POCT Strips through Accelerated Degradation Test. *Pharm Anal Acta.* 2016;7:475.
83. Abdou EM and Ahmed NM. Terconazole Proniosomal Gels: Effect of Different Formulation Factors, Physicochemical and Microbiological Evaluation. *J Pharm Drug Deliv Res.* 2016;5:1.
84. Adesina SK, et al. Nanoparticle Characteristics Affecting Efficacy. *J Pharm Drug Deliv Res.* 2016;5:1.
85. Parteni O, et al. The Release of Tacrolimus from a Cotton Biomaterial to Dermis. *J Pharm Drug Deliv Res.* 2016;5:1.
86. Girolamo L, et al. Blood Volume Determination Through New Generation 130/0,4 Hydroxyethyl-Starch: A Propaedeutic, In-Vitro Study. *Pharm Anal Acta.* 2015;6:441.

87. Balekari U and Veeresham C. Insulinotropic Agents from Medicinal Plants. *J Pharm Sci Emerg Drugs*. 2014;2:1.
88. Ferreira H, et al. Deformable Liposomes for the Transdermal Delivery of Piroxicam. *J Pharm Drug Deliv Res*. 2015;4:4.
89. Rana VS. Separation and Identification of Swertiamarin from *Enicostema axillare* Lam. Raynal by Centrifugal Partition Chromatography and Nuclear Magnetic Resonance-Mass Spectrometry. *J Pharm Sci Emerg Drugs*. 2014;2:1.
90. Resende GD, et al. First Dose Combination Studies of Anti-Tuberculosis Drugs With Piperic Acid. *J Pharm Sci Emerg Drugs*. 2014;2:1.
91. Chiririwa H. Synthesis, Characterization of Gold (III) Complexes and an in vitro Evaluation of their Cytotoxic Properties. *J Pharm Sci Emerg Drugs*. 2014;2:1.
92. Joshi RR and Devarajan PV Anionic Self Micro-Emulsifying Drug Delivery System (SMEDDS) Of Docetaxel for Circulation Longevity. *J Pharm Drug Deliv Res*. 2015;4:3.
93. Naik DR, et al. Release Kinetics of Cellulosic Nano particulate Formulation for Oral Administration of an Antiviral Drug: Effect of Process and Formulation variables. *J Pharm Sci Emerg Drugs*. 2014;2:1.
94. Patel MN, et al. Synthesis, Characterization and Biological Elucidation of Mixed Ligand Cu (II) Complexes as Artificial Metallonucleases. *J Pharm Sci Emerg Drugs*. 2015;3:1.
95. Swapnil S, et al. Healing Potential of *Citrullus Lanatus* in Acetic Acid Induced Ulcerated Rats. *J Pharm Sci Emerg Drugs*. 2015;3:1.
96. Koly SF, et al. An In Vitro Study of Binding of Aceclofenac and Pantoprazole with Bovine Serum Albumin by UV Spectroscopic Method. *J Pharm Sci Emerg Drugs*. 2016;4:1.
97. Akpoto K and Kokou K et al. Impact of Small-Scale Logging in Semi Deciduous Forest of Togo (West Africa). *J Biodivers Manage Forestry* 2015;4:1.
98. Mengesha G and Mamo Y et al. Abundance and Temporal Patterns in Wetland Birds in and Around Lake Zeway, Ethiopia. *J Biodivers Manage Forestry* 2015;4:1.
99. Rahman SS and Vacik H. Identify Appropriate Conservation Strategies for Rural People in Bangladesh. *J Biodivers Manage Forestry* 2015;4:1.
100. Stover KC and Keyes CR et al. Forest Fuels and Wildfire Hazard in Two Fire-Excluded Old-Growth Ponderosa Pine Stands: Contrasting Stand-Average Calculations with Measures of Spatial Heterogeneity. *J Biodivers Manage Forestry* 2015;5:2.